Abstract
Aspirin (ASA) is recommended for the prevention of cardiovascular disease; however, the compliance is low. Reported use may not reflect actual use. Serum thromboxane B2 (STxB2) measurement was evaluated to validate reported ASA use. Males aged 45 to 79 years and females aged 55 to 79 years completed a survey and STxB2 measurement (Thromboxane B 2 EIA Kit; Cayman Chemical, Ann Arbor, Michigan). The 107 patients were grouped by use of ASA (56 ASA+ and 51 ASA-) and possible interfering medications (INT) such as nonsteroidal anti-inflammatory drugs. The STxB 2 levels (ng/mL) were significantly lower in ASA users: ASA+ INT- 3.0 (0.7, 8.4), ASA+ INT+ 2.0 (0.8, 4.9), ASA- INT+ 176 (75, 390), and ASA- INT- 271 (199, 366). The INT use did not cause a significant difference in STxB 2 levels. A STxB2 cut point of 25 ng/mL had high sensitivity (94.1%) and specificity (91.1%) for ASA use. The STxB2 was a reliable marker of ASA use and could be used to confirm ASA exposure in population-based health studies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 385-392 |
| Number of pages | 8 |
| Journal | Clinical and Applied Thrombosis/Hemostasis |
| Volume | 20 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jan 1 2014 |
Fingerprint
Keywords
- NSAID
- aspirin
- cardiovascular prevention
- compliance
- nonsteroidal anti-inflammatory drug
Cite this
Confirmation of reported aspirin use in community studies : Utility of serum thromboxane B2 measurement. / Zantek, Nicole D; Luepker, Russell V; Duval, Sue; Miller, Karen; Oldenburg, Niki; Hirsch, Alan T.
In: Clinical and Applied Thrombosis/Hemostasis, Vol. 20, No. 4, 01.01.2014, p. 385-392.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Confirmation of reported aspirin use in community studies
T2 - Utility of serum thromboxane B2 measurement
AU - Zantek, Nicole D
AU - Luepker, Russell V
AU - Duval, Sue
AU - Miller, Karen
AU - Oldenburg, Niki
AU - Hirsch, Alan T
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Aspirin (ASA) is recommended for the prevention of cardiovascular disease; however, the compliance is low. Reported use may not reflect actual use. Serum thromboxane B2 (STxB2) measurement was evaluated to validate reported ASA use. Males aged 45 to 79 years and females aged 55 to 79 years completed a survey and STxB2 measurement (Thromboxane B 2 EIA Kit; Cayman Chemical, Ann Arbor, Michigan). The 107 patients were grouped by use of ASA (56 ASA+ and 51 ASA-) and possible interfering medications (INT) such as nonsteroidal anti-inflammatory drugs. The STxB 2 levels (ng/mL) were significantly lower in ASA users: ASA+ INT- 3.0 (0.7, 8.4), ASA+ INT+ 2.0 (0.8, 4.9), ASA- INT+ 176 (75, 390), and ASA- INT- 271 (199, 366). The INT use did not cause a significant difference in STxB 2 levels. A STxB2 cut point of 25 ng/mL had high sensitivity (94.1%) and specificity (91.1%) for ASA use. The STxB2 was a reliable marker of ASA use and could be used to confirm ASA exposure in population-based health studies.
AB - Aspirin (ASA) is recommended for the prevention of cardiovascular disease; however, the compliance is low. Reported use may not reflect actual use. Serum thromboxane B2 (STxB2) measurement was evaluated to validate reported ASA use. Males aged 45 to 79 years and females aged 55 to 79 years completed a survey and STxB2 measurement (Thromboxane B 2 EIA Kit; Cayman Chemical, Ann Arbor, Michigan). The 107 patients were grouped by use of ASA (56 ASA+ and 51 ASA-) and possible interfering medications (INT) such as nonsteroidal anti-inflammatory drugs. The STxB 2 levels (ng/mL) were significantly lower in ASA users: ASA+ INT- 3.0 (0.7, 8.4), ASA+ INT+ 2.0 (0.8, 4.9), ASA- INT+ 176 (75, 390), and ASA- INT- 271 (199, 366). The INT use did not cause a significant difference in STxB 2 levels. A STxB2 cut point of 25 ng/mL had high sensitivity (94.1%) and specificity (91.1%) for ASA use. The STxB2 was a reliable marker of ASA use and could be used to confirm ASA exposure in population-based health studies.
KW - NSAID
KW - aspirin
KW - cardiovascular prevention
KW - compliance
KW - nonsteroidal anti-inflammatory drug
UR - http://www.scopus.com/inward/record.url?scp=84899028752&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899028752&partnerID=8YFLogxK
U2 - 10.1177/1076029613486537
DO - 10.1177/1076029613486537
M3 - Article
VL - 20
SP - 385
EP - 392
JO - Clinical and Applied Thrombosis/Hemostasis
JF - Clinical and Applied Thrombosis/Hemostasis
SN - 1076-0296
IS - 4
ER -